
Avisi is a medical devices startup investigating the use of patented nanotechnology in an ocular implant to stop blindness in glaucoma patients.
Glaucoma is the second leading cause of blindness in the world and currently has no cure.
To date, Avisi has been supported by grants and awards from: the National Science Foundation, Ben Franklin Technology Partners, the University of Pennsylvania, Wharton, The School of Engineering and Applied Science, Venture Initiation Program Accelerator (VIP-X), Penn Law's Entrepreneurship Legal Clinic, VentureWell E-Teams, and Ballard Spahr BASE.
Avisi is a proud member of Johnson & Johnson JLABS incubator, UCSF Rosenman Innovators, OC OCTANE LaunchPad, and MedTech Innovator Accelerator.
Twitter: @avisi_tech
Website: www.avisitech.com
Glaucoma is the second leading cause of blindness in the world and currently has no cure.
To date, Avisi has been supported by grants and awards from: the National Science Foundation, Ben Franklin Technology Partners, the University of Pennsylvania, Wharton, The School of Engineering and Applied Science, Venture Initiation Program Accelerator (VIP-X), Penn Law's Entrepreneurship Legal Clinic, VentureWell E-Teams, and Ballard Spahr BASE.
Avisi is a proud member of Johnson & Johnson JLABS incubator, UCSF Rosenman Innovators, OC OCTANE LaunchPad, and MedTech Innovator Accelerator.
Twitter: @avisi_tech
Website: www.avisitech.com
Location: United States, Pennsylvania, Philadelphia
Employees: 1-10
Total raised: $5.1M
Founded date: 2017
Investors 4
Date | Name | Website |
05.01.2021 | Life Scien... | lifescienc... |
- | Ben Frankl... | sep.benfra... |
- | Good Growt... | goodgrowth... |
- | K2X | k2x.capita... |
Funding Rounds 2
Date | Series | Amount | Investors |
01.07.2022 | Seed | $4.1M | Life Scien... |
21.09.2020 | Grant | $1M | - |
Mentions in press and media 5
Date | Title | Description |
18.10.2021 | Ben Franklin Approved $2.1M in 12 Early Stage Companies | |
27.10.2020 | Ben Franklin Approved $1.1M in 5 Early Stage Companies | |
21.09.2020 | Avisi Technologies eyes goal of human trials with $1M National Science Foundation grant | RealLIST Startups 2020 honoree Avisi Technologies, maker of an ocular implant to treat glaucoma, is the recent recipient of a $1 million Small Business Innovation Research Phase II grant from the National Science Foundation (NSF) — funds co... |
25.07.2019 | Ben Franklin Approved 1.3M in 9 Early Stage Companies | |
- | Avisi Technologies | “Avisi Technologies is developing a nanotechnology-enabled defense against blindness from glaucoma.” |